Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Tizona Therapeutics, Inc
Second Life Therapeutics
Pfizer
Numab Therapeutics AG
Ikena Oncology
Ikena Oncology
Multitude Therapeutics Inc.
Novartis
MacroGenics
University of Washington
Bayer
University of Washington